Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Multiple sclerosis

TOWER confirms the efficacy of oral teriflunomide in MS

Nature Reviews Neurology volume 10, pages 183–184 (2014)Cite this article

Subjects

Results of the TOWER phase III trial confirm the efficacy of teriflunomide in relapsing–remitting multiple sclerosis (RRMS). With seven substances now approved for RRMS, individualized treatment for the inflammatory aspect of the disease is within reach, although many questions remain unanswered, particularly concerning the neurodegenerative aspect RRMS.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Cellular effects of teriflunomide.

References

  1. Confavreux, C. et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 13, 247–256 (2014).

    Article  CAS  PubMed  Google Scholar 

  2. O'Connor, P. et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N. Engl. J. Med. 365, 1293–1303 (2011).

    Article  CAS  PubMed  Google Scholar 

  3. O'Connor, P. W. et al. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66, 894–900 (2006).

    Article  CAS  PubMed  Google Scholar 

  4. Gold, R. & Wolinsky, J. S. Pathophysiology of multiple sclerosis and the place of teriflunomide. Acta Neurol. Scand. 124, 75–84 (2011).

    Article  CAS  PubMed  Google Scholar 

  5. Bar-Or, A. et al. Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis. Neurology 81, 552–558 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Vermersch, P. et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult. Scler. http://dx.doi.org/10.1177/1352458513507821.

  7. Freedman, M. S. et al. Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial. Neurology 78, 1877–1885 (2012).

    Article  CAS  PubMed  Google Scholar 

  8. Korn, T., Toyka, K., Hartung, H. P. & Jung, S. Suppression of experimental autoimmune neuritis by leflunomide. Brain 124, 1791–1802 (2001).

    Article  CAS  PubMed  Google Scholar 

  9. Fuentealba, R. A., Marasa, J., Diamond, M. I., Piwnica-Worms, D. & Weihl, C. C. An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors. Hum. Mol. Genet. 21, 664–680 (2012).

    Article  CAS  PubMed  Google Scholar 

  10. Haghikia, A., Hohlfeld, R., Gold, R. & Fugger, L. Therapies for multiple sclerosis: translational achievements and outstanding needs. Trends Mol. Med. 19, 309–319 (2013).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology of the Ruhr-University Bochum at St Josef-Hospital, Gudrunstrasse 56, 44791, Bochum, Germany

    Aiden Haghikia & Ralf Gold

Authors
  1. Aiden Haghikia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ralf Gold
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ralf Gold.

Ethics declarations

Competing interests

R.G. has received speakers' honoraria from Baxter, Bayer Schering, Biogen Idec, CLB Behring, Genzyme, Merck Serono, Novartis, Talecris, TEVA and Wyeth. His department has received grants from Bayer Schering, Biogen Idec, Genzyme, Merck Serono, Novartis and TEVA. A.H. declares no competing interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Haghikia, A., Gold, R. TOWER confirms the efficacy of oral teriflunomide in MS. Nat Rev Neurol 10, 183–184 (2014). https://doi.org/10.1038/nrneurol.2014.42

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2014.42

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing